Cathay Biotech Inc. (SHA:688065)
China · Delayed Price · Currency is CNY 38.34
-0.98 (-2.49%)
Sep 24, 2026, 3:00 PM CST
Cathay Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 27,630 | 35,889 | 22,555 | 32,012 | 35,749 | 76,786 | |
Market Cap Growth | -24.51% | 59.12% | -29.54% | -10.45% | -53.44% | 116.67% |
Enterprise Value | 22,866 | 30,779 | 22,818 | 31,823 | 33,878 | 71,142 |
Last Close Price | 38.34 | 49.30 | 38.09 | 53.71 | 59.71 | 127.69 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.80 | 64.01 | 46.13 | 87.34 | 64.61 | 129.11 |
Forward PE | 31.62 | 48.47 | 29.61 | 46.74 | 38.31 | 89.61 |
PS Ratio | 7.84 | 10.89 | 7.63 | 15.14 | 14.65 | 32.49 |
PB Ratio | 1.28 | 1.68 | 1.49 | 2.17 | 2.38 | 5.23 |
P/TBV Ratio | 1.65 | 2.12 | 2.08 | 3.06 | 3.52 | 7.77 |
P/OCF Ratio | 33.88 | 88.81 | 27.48 | 56.22 | 44.48 | 132.69 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.49 | 9.34 | 7.71 | 15.05 | 13.88 | 30.10 |
EV/EBITDA Ratio | 23.53 | 36.76 | 31.81 | 70.52 | 50.43 | 106.53 |
EV/EBIT Ratio | 34.54 | 58.43 | 57.61 | 192.23 | 83.32 | 142.50 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.02 | 0.13 | 0.12 | 0.08 | 0.05 |
Debt / EBITDA Ratio | 0.73 | 0.60 | 2.65 | 3.94 | 1.68 | 1.11 |
Net Debt / Equity Ratio | -0.40 | -0.41 | -0.23 | -0.24 | -0.34 | -0.61 |
Net Debt / EBITDA Ratio | -8.84 | -10.45 | -4.81 | -8.01 | -7.69 | -13.31 |
Net Debt / FCF Ratio | 70.50 | 25.78 | 154.13 | 3.61 | 1.52 | 10.09 |
Asset Turnover | 0.15 | 0.15 | 0.16 | 0.12 | 0.14 | 0.17 |
Inventory Turnover | 1.85 | 1.76 | 1.60 | 1.01 | 1.17 | 1.56 |
Quick Ratio | 4.35 | 4.87 | 1.99 | 1.70 | 4.75 | 8.14 |
Current Ratio | 5.25 | 5.85 | 2.53 | 2.22 | 5.95 | 9.36 |
Return on Equity (ROE) | 2.88% | 2.91% | 3.18% | 2.74% | 4.12% | 4.84% |
Return on Assets (ROA) | 1.71% | 1.54% | 1.31% | 0.56% | 1.49% | 2.20% |
Return on Invested Capital (ROIC) | 4.35% | 3.66% | 3.01% | 1.43% | 4.57% | 8.53% |
Return on Capital Employed (ROCE) | 3.00% | 2.40% | 2.50% | 1.10% | 2.50% | 3.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.26% | 1.56% | 2.17% | 1.15% | 1.55% | 0.78% |
FCF Yield | -0.44% | -0.95% | -0.10% | -3.13% | -9.50% | -1.15% |
Dividend Yield | 1.17% | 0.91% | 1.05% | 0.35% | 0.30% | 0.25% |
Payout Ratio | 48.72% | 55.84% | 28.80% | 37.58% | 37.39% | 57.11% |
Buyback Yield / Dilution | -15.90% | -17.47% | -0.05% | 0.10% | 0.11% | -7.38% |
Total Shareholder Return | -14.73% | -16.56% | 1.00% | 0.46% | 0.42% | -7.13% |